CHAPEL HILL, N.C., Nov. 28 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of candidates for the treatment of migraine, today announced that two late-stage Phase III clinical trials for its lead product candidate, MT 100, have been completed.

CHAPEL HILL, N.C., Nov. 8 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company whose lead product candidate for the treatment of migraine is in late Phase III clinical trials, today announced results for the first time as a public company.

CHAPEL HILL, N.C., Nov. 7 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of migraine products, today announced that the underwriters of its initial public offering have purchased an additional 750,000 shares of common stock at $15 per share pursuant

CHAPEL HILL, N.C., Nov. 6 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of migraine products, today announced it plans to conduct a conference call following the release of financial results for the third quarter ended September 30, 2000.

CHAPEL HILL, NC – November 22, 1999 – POZEN Inc. today announced that the company has acquired an exclusive worldwide license to a novel serotonin (5-HT2B) receptor antagonist discovered by F. Hoffmann-La Roche, Ltd. The compound, now known as MT 500, will be the first drug developed specifically